James N. McGuire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James N. McGuire has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Flemming Pociot
Translational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center Copenhagen
3 shared publications - Anne Julie Overgaard
Hagedorn Research Institute, Novo Nordisk A/S, Gentofte, Denmark
2 shared publications - Henning Gram Hansen
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark
2 shared publications - Lise Tarnow
Steno Diabetes Center Copenhagen, Gentofte, Denmark
2 shared publications - Peter Rossing
Steno Diabetes Center Copenhagen Denmark
2 shared publications Ana M. Wägner
Department Medical and Surgical Sciences, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria 35001, Spain
1 shared publication
Latest Publications
- 14 September 2010
- Published by Taylor & Francis in Archives of Physiology and Biochemistry
- Vol. 116 (4-5) , 227-232
Screening newborns for candidate biomarkers of type 1 diabetes
Combining samples from a national neonatal screening programme with the information from a national health registry allow for unique opportunities in analysing newborn blood for protein changes that could predict eventual disease development. A nested case-control cohort (n = 54 cases, 108 controls) was analysed by proteomics as a new way of looking for biomarkers that could bolster prediction of T1D risk in newborns. Protein extraction and haemoglobin depletion were automated and samples were processed and analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). The data set was reduced to the highest quality peaks and analysed using conditional logistic regression. A total of 25 protein peaks were found to differ between the two groups. The automated haemoglobin depletion provides a platform for further proteomics studies of individual patient material. The method opens a door to a wealth of patient material stored as dried blood spots.
- 14 September 2010
- Published by Taylor & Francis in Archives of Physiology and Biochemistry
- Vol. 116 (4-5) , 227-232
Screening newborns for candidate biomarkers of type 1 diabetes
Combining samples from a national neonatal screening programme with the information from a national health registry allow for unique opportunities in analysing newborn blood for protein changes that could predict eventual disease development. A nested case-control cohort (n = 54 cases, 108 controls) was analysed by proteomics as a new way of looking for biomarkers that could bolster prediction of T1D risk in newborns. Protein extraction and haemoglobin depletion were automated and samples were processed and analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). The data set was reduced to the highest quality peaks and analysed using conditional logistic regression. A total of 25 protein peaks were found to differ between the two groups. The automated haemoglobin depletion provides a platform for further proteomics studies of individual patient material. The method opens a door to a wealth of patient material stored as dried blood spots.
- 29 April 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (8-9) , 697-705
Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis
Purpose and experimental design: Diabetic nephropathy (DN) is the most common cause of end‐stage renal disease and improved biomarkers would help identify high‐risk individuals. The aim of this study was to discover candidate biomarkers for DN in the plasma peptidome in an in‐house cross‐sectional cohort (n=122) of type 1 diabetic patients diagnosed with normo‐, micro‐, and macroalbuminuria. Results: Automated, high‐throughput, and reproducible (interassay median CV: 13–14%) plasma peptide profiling protocols involving RPC18 and weak cation exchange magnetic beads on a liquid handling workstation with a MALDI‐TOF‐MS readout were successfully established. Using these protocols and a combined univariate (Kruskal–Wallis) and multivariate (independent component analysis) statistical analysis approach, ten single peptides and three multi‐peptide candidate biomarkers were found. Employment of RPC18 and weak cation exchange magnetic beads proved to be complementary. Conclusions and clinical relevance: The proteins found in this study, including C3f and apolipoprotein C‐I, represent new candidate biomarkers for DN from the plasma peptidome. The automated procedures and implementation of independent components analysis provide a fast and informative system for analyzing individual patient samples in protein biomarker discovery.
- 29 April 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (8-9) , 697-705
Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis
Purpose and experimental design: Diabetic nephropathy (DN) is the most common cause of end‐stage renal disease and improved biomarkers would help identify high‐risk individuals. The aim of this study was to discover candidate biomarkers for DN in the plasma peptidome in an in‐house cross‐sectional cohort (n=122) of type 1 diabetic patients diagnosed with normo‐, micro‐, and macroalbuminuria. Results: Automated, high‐throughput, and reproducible (interassay median CV: 13–14%) plasma peptide profiling protocols involving RPC18 and weak cation exchange magnetic beads on a liquid handling workstation with a MALDI‐TOF‐MS readout were successfully established. Using these protocols and a combined univariate (Kruskal–Wallis) and multivariate (independent component analysis) statistical analysis approach, ten single peptides and three multi‐peptide candidate biomarkers were found. Employment of RPC18 and weak cation exchange magnetic beads proved to be complementary. Conclusions and clinical relevance: The proteins found in this study, including C3f and apolipoprotein C‐I, represent new candidate biomarkers for DN from the plasma peptidome. The automated procedures and implementation of independent components analysis provide a fast and informative system for analyzing individual patient samples in protein biomarker discovery.
- Open Access
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 4
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
As part of a clinical proteomics program focused on diabetes and its complications we are looking for new and better protein biomarkers for diabetic nephropathy. The search for new and better biomarkers for diabetic nephropathy has, with a few exceptions, previously focused on either hypothesis-driven studies or urinary based investigations. To date only two studies have investigated the proteome of blood in search for new biomarkers, and these studies were conducted in sera from patients with type 2 diabetes. This is the first reported in depth proteomic study where plasma from type 1 diabetic patients was investigated with the goal of finding improved candidate biomarkers to predict diabetic nephropathy. In order to reach lower concentration proteins in plasma a pre-fractionation step, either hexapeptide bead-based libraries or anion exchange chromatography, was performed prior to surface enhanced laser desorption/ionization time-of-flight mass spectrometry analysis. Proteomic analysis of plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric, gave rise to 290 peaks clusters of which 16 were selected as the most promising biomarker candidates based on statistical performance, including independent component analysis. Four of the peaks that were discovered have been identified as transthyretin, apolipoprotein A1, apolipoprotein C1 and cystatin C. Several yet unidentified proteins discovered by this novel approach appear to have more potential as biomarkers for diabetic nephropathy. These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic patients.
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 4
Open AccessPlasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
As part of a clinical proteomics program focused on diabetes and its complications we are looking for new and better protein biomarkers for diabetic nephropathy. The search for new and better biomarkers for diabetic nephropathy has, with a few exceptions, previously focused on either hypothesis-driven studies or urinary based investigations. To date only two studies have investigated the proteome of blood in search for new biomarkers, and these studies were conducted in sera from patients with type 2 diabetes. This is the first reported in depth proteomic study where plasma from type 1 diabetic patients was investigated with the goal of finding improved candidate biomarkers to predict diabetic nephropathy. In order to reach lower concentration proteins in plasma a pre-fractionation step, either hexapeptide bead-based libraries or anion exchange chromatography, was performed prior to surface enhanced laser desorption/ionization time-of-flight mass spectrometry analysis. Proteomic analysis of plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric, gave rise to 290 peaks clusters of which 16 were selected as the most promising biomarker candidates based on statistical performance, including independent component analysis. Four of the peaks that were discovered have been identified as transthyretin, apolipoprotein A1, apolipoprotein C1 and cystatin C. Several yet unidentified proteins discovered by this novel approach appear to have more potential as biomarkers for diabetic nephropathy. These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic patients.